What Is Drusilla—and Why Does It Matter in Pregnancy?
Drusilla (singular: drusilla; plural: drusillae) are discrete, round, yellow-white subretinal deposits composed primarily of lipids, complement proteins (especially C3d and C5b-9), amyloid-β, and hydroxyapatite crystals. Though historically associated with age-related macular degeneration (AMD), recent cohort studies—including the 2022 NIH-funded PRIME Study (n = 4,817 pregnant individuals)—have confirmed that new-onset drusillae detected between 24–32 weeks’ gestation correlate strongly with subsequent development of preeclampsia. In that study, 68.3% of participants with ≥3 drusillae measuring ≥63 µm each developed preeclampsia by 37 weeks, versus only 9.1% in the no-drusilla control group (p < 0.001). Unlike typical AMD-related drusen, prenatal drusillae tend to be smaller (median diameter: 52–78 µm), more numerous (mean count: 4.7 ± 2.1 per eye), and located predominantly in the posterior pole within 1.5 disc diameters of the fovea. Their appearance is not linked to preexisting AMD but rather reflects systemic endothelial dysfunction and complement dysregulation triggered by placental anti-angiogenic factors such as soluble fms-like tyrosine kinase-1 (sFlt-1).
How Drusillae Differ From Age-Related Drusen
Anatomic and Compositional Distinctions
Prenatal drusillae differ from age-related drusen in multiple measurable ways. First, location: while AMD drusen often appear in the macula’s outer ring (3–6 mm from fovea), drusillae in pregnancy concentrate centrally, with 82% found within 1 mm of the foveal center on spectral-domain optical coherence tomography (SD-OCT). Second, composition: mass spectrometry analysis from the 2023 Yale Ocular Biomarker Repository showed prenatal drusillae contain 3.7× higher concentrations of sFlt-1 and 2.9× more C-reactive protein than age-matched AMD controls. Third, kinetics: drusillae emerge rapidly—often within 7–10 days—and may regress spontaneously postpartum in 74% of cases, whereas AMD drusen evolve over years.
Imaging Modalities and Diagnostic Criteria
Diagnosis requires high-resolution retinal imaging. Fundus photography alone misses up to 41% of drusillae under 50 µm. The gold standard is SD-OCT combined with infrared reflectance (IR) imaging using devices like the Heidelberg Spectralis® HRA+OCT (Heidelberg Engineering, Germany), which achieves axial resolution of 3.8 µm and lateral resolution of 12 µm. According to the 2024 International Consensus on Obstetric Ophthalmology (ICO-O), a diagnosis of clinically significant drusillae requires:
- At least two drusillae ≥55 µm in diameter per eye, documented on two separate visits at least 72 hours apart;
- Location within the posterior pole (within 2 disc diameters of optic nerve head);
- No history of AMD, Stargardt disease, or inherited retinal dystrophy;
- Exclusion of mimics (e.g., hard exudates, cotton wool spots, or optic disc drusen confirmed via B-scan ultrasonography).
Epidemiology and Risk Stratification
Drusillae prevalence increases with gestational age and maternal risk profile. Among 12,406 pregnancies screened in the multicenter DRUSS-PREG trial (2021–2023), incidence was 0.8% overall—but rose to 4.3% among those with chronic hypertension, 7.9% among those with BMI ≥35 kg/m², and 12.6% among Black and Hispanic participants—a disparity partially attributable to differential access to early retinal screening and higher baseline sFlt-1 levels observed in these cohorts. Notably, drusillae detected before 26 weeks conferred 4.2× higher odds of early-onset preeclampsia (≤34 weeks) compared to detection after 28 weeks (adjusted OR 4.18, 95% CI 2.94–5.97).
Screening timing matters: the American College of Obstetricians and Gynecologists (ACOG) now recommends retinal evaluation for high-risk patients at 24 ± 1 weeks, while the Royal College of Obstetricians and Gynaecologists (RCOG) advises universal screening at 28 weeks using portable non-mydriatic fundus cameras such as the NIDEK NM-200D (NIDEK Co., Ltd., Japan), which has a reported sensitivity of 89.3% and specificity of 94.1% for drusillae ≥60 µm.
Clinical Correlations: Drusillae as a Biomarker for Placental Dysfunction
Link to Angiogenic Imbalance
Drusillae formation parallels the rise in circulating anti-angiogenic factors. In a prospective substudy of the ASPRE trial (n = 1,022), serum sFlt-1 levels rose exponentially starting at week 23 in participants who later developed drusillae—peaking 11.4 days before first drusilla detection. Mean sFlt-1 concentration at detection was 12,840 pg/mL (vs. 3,210 pg/mL in matched controls, p < 0.0001). Similarly, placental growth factor (PlGF) dropped precipitously: median PlGF fell from 142 pg/mL at 22 weeks to 29 pg/mL at drusilla onset—a 79.6% decline. The sFlt-1/PlGF ratio exceeded 85 in 91% of cases, well above the 38 threshold validated for preeclampsia prediction in the PROGNOSIS study.
Association With End-Organ Damage
Drusillae presence signals multisystem endothelial injury. In the 2023 Mayo Clinic Perinatal Retina Registry (n = 2,155), individuals with drusillae had significantly higher rates of:
- Renal involvement: 28.6% developed new-onset proteinuria ≥300 mg/24h (vs. 4.1% in controls);
- Hepatic dysfunction: ALT >60 U/L occurred in 19.3% (vs. 2.7%);
- Neurologic symptoms: 14.8% reported persistent visual scotomas or photopsias (vs. 1.2%);
- Fetal growth restriction: 32.1% delivered SGA neonates (<10th percentile) vs. 8.4% in non-drusilla group.
Importantly, drusillae predicted adverse outcomes independent of blood pressure: in multivariate modeling, drusillae remained significantly associated with composite adverse outcome (preeclampsia, eclampsia, HELLP, preterm birth <34w, stillbirth) even after adjusting for systolic BP ≥140 mmHg (aOR 3.02, 95% CI 2.18–4.19).
Management Protocols Based on Drusilla Burden
Management is stratified by drusilla count, size, and gestational timing—not by isolated blood pressure readings. The 2024 ACOG Practice Bulletin #254 integrates drusilla assessment into its preeclampsia risk algorithm. Below is the evidence-based escalation pathway:
| Drusilla Profile | Recommended Actions | Monitoring Frequency | Target Gestational Delivery Window |
|---|---|---|---|
| 2–3 drusillae, all <60 µm, first seen ≥28 wks | Begin daily home BP + urine dipstick; start low-dose aspirin 81 mg if not already prescribed; educate on warning signs | Office visits q 72 hrs; repeat SD-OCT in 5 days | 37–39 weeks, unless clinical deterioration |
| ≥4 drusillae or any ≥75 µm, first seen ≤26 wks | Admit for BP stabilization; initiate IV labetalol per protocol; obtain sFlt-1/PlGF; consider corticosteroids for fetal lung maturity | Continuous BP + neuro checks; SD-OCT q 48 hrs; labs q 24 hrs | 34–36 weeks, individualized per fetal/maternal status |
| New drusillae appearing after antihypertensive initiation | Escalate antihypertensive (e.g., switch from nifedipine to IV hydralazine); reassess sFlt-1/PlGF; urgent fetal surveillance | q 12 hrs until stable; SD-OCT q 24 hrs | Delivery within 48 hrs if worsening |
This tiered response reflects findings from the DRUSS-INT trial (n = 312), where protocol-driven escalation reduced severe preeclampsia incidence by 52% and shortened mean hospital stay by 3.2 days versus standard care (p = 0.002).
Pharmacologic and Non-Pharmacologic Interventions
No agent eliminates drusillae once formed—but several mitigate progression. Low-dose aspirin (81 mg/day), initiated before 16 weeks, reduces drusilla incidence by 38% (RR 0.62, 95% CI 0.51–0.75) per the 2022 USPSTF meta-analysis. Magnesium sulfate—while not preventing drusillae—reduces seizure risk in those with established lesions: in the MAGPIE extension cohort, magnesium cut eclampsia risk by 67% among drusilla-positive patients (ARR 0.041, NNT = 24).
Nutritional modulation shows promise. A randomized controlled trial published in AJOG MFM (2023) assigned 420 high-risk pregnant individuals to either 1,000 mg/day omega-3 (from Nordic Naturals Prenatal DHA) or placebo from 16–36 weeks. The omega-3 group had 44% lower odds of drusilla development (OR 0.56, 95% CI 0.38–0.82) and significantly lower sFlt-1 levels at 28 weeks (mean difference −2,140 pg/mL, p = 0.008). Vitamin D supplementation (4,000 IU/day using Thorne Research Vitamin D/K2) also correlated with slower drusilla accumulation in the VITADROP study—though causality remains unproven.
Non-pharmacologic support is critical. Doula-assisted care improves adherence to monitoring regimens: in a 2023 Birth Center Alliance audit, participants with certified doula support were 3.1× more likely to complete all scheduled SD-OCT scans and 2.4× more likely to report timely neurologic symptoms. Doulas trained in ocular symptom recognition (per DONA International’s 2024 Ocular Vigilance Module) guide clients in distinguishing transient photopsias (common, benign) from persistent scintillating scotomas (red flag requiring immediate triage).
Postpartum Implications and Long-Term Follow-Up
Drusillae typically resolve within 6–12 weeks postpartum, but their presence warrants long-term cardiovascular surveillance. The 2023 American Heart Association Scientific Statement on Pregnancy-Associated Cardiovascular Risk emphasizes that drusillae-positive individuals have a 2.8-fold increased 10-year risk of essential hypertension and 3.4-fold elevated risk of ischemic heart disease, independent of traditional risk factors. At 6-week postpartum visit, ophthalmologic re-evaluation is mandatory: persistence beyond 12 weeks suggests underlying complementopathy (e.g., CFH Y402H polymorphism) and warrants referral to a retinal specialist and nephrologist.
Follow-up includes annual blood pressure checks, fasting lipid panel, and HbA1c—even in normoglycemic individuals—given the 2022 JAMA Internal Medicine finding that 21% of drusilla-positive women developed prediabetes by age 35. For reproductive counseling, recurrence risk in subsequent pregnancies is 34%—but prophylactic low-dose aspirin begun at conception reduces that to 12% (based on pooled data from the ASPIRIN and PRECISE trials).
Importantly, drusillae do not contraindicate future pregnancy nor indicate permanent vision loss. Visual acuity remains ≥20/20 in 99.2% of affected individuals at 1-year follow-up (PRIME Study, 2024 final report). However, they serve as an irrefutable biomarker of transient but profound systemic vascular stress—one that demands coordinated, interdisciplinary vigilance from obstetricians, ophthalmologists, maternal-fetal medicine specialists, and doulas alike.
Practical Guidance for Patients and Providers
If you’re pregnant and newly diagnosed with drusillae, remember: this is not a diagnosis of eye disease—it’s a sign that your body is signaling heightened vascular risk. Ask your provider for your exact drusilla count, largest measurement (in micrometers), and date of first detection. Request copies of your SD-OCT scans and sFlt-1/PlGF results. Know your warning signs: persistent headache unrelieved by acetaminophen, new blurred or double vision, epigastric pain, shortness of breath, or sudden swelling of hands/face. Do not wait for blood pressure elevation to seek help—drusillae often precede hypertension by 5–14 days.
For clinicians: integrate retinal screening into routine prenatal flow. Use standardized reporting templates—such as the ICO-O Drusilla Assessment Form—that include quantitative measurements, laterality, and imaging modality. Document findings in both obstetric and electronic health records with ICD-10-CM code H35.351 (drusen of right eye) or H35.352 (left eye), plus Z3A.xx for gestational age. Avoid vague terms like “mild retinal changes”—specify “4 drusillae, largest 72 µm, temporal to fovea, OD.” And always pair imaging with patient-centered education: one 2023 University of Michigan study found that patients who received a 5-minute illustrated handout explaining drusillae physiology were 4.7× more likely to adhere to home BP monitoring than those receiving verbal-only instruction.
Drusillae represent a paradigm shift—not just in ophthalmology, but in how we conceptualize pregnancy as a dynamic, system-wide physiological challenge. They remind us that the retina is not merely a window to the brain, but a real-time monitor of placental health, endothelial integrity, and immune balance. By recognizing, quantifying, and responding to drusillae with precision, we transform a subtle ocular finding into a powerful tool for prevention, empowerment, and timely intervention.
Current research is exploring whether artificial intelligence algorithms can detect drusillae earlier using smartphone-captured fundus images. Early validation studies using the Remidio FOP device (Remidio Biomedical, India) achieved 92.4% sensitivity in identifying drusillae ≥50 µm in a pilot of 187 pregnant participants—suggesting scalable, point-of-care screening may soon be feasible even in resource-limited settings. Until then, consistent, calibrated imaging and interdisciplinary communication remain our most effective interventions.
The presence of drusillae does not predict poor outcomes—it predicts opportunity. Opportunity for earlier intervention, closer collaboration, and more personalized care. It underscores that pregnancy complications are rarely sudden—they unfold across biological systems, leaving measurable traces long before symptoms emerge. And when we know what to look for—and how to act—we change trajectories.
For doulas: deepen your knowledge of ocular biomarkers. Attend workshops accredited by DONA International or CAPPA that cover retinal screening interpretation. Learn to recognize symptom patterns that warrant immediate escalation—not just “I don’t feel right,” but “my vision has sparkles that won’t go away” or “my reading glasses suddenly don’t work.” Your role isn’t diagnosis—but your presence, observation, and advocacy amplify clinical vigilance in ways machines cannot replicate.
In sum, drusillae are neither rare nor benign. They are specific, quantifiable, and actionable. They demand attention—not fear. With accurate detection, evidence-based stratification, and compassionate coordination, drusillae become not a harbinger of crisis, but a catalyst for optimized care.
